161 related articles for article (PubMed ID: 25257248)
1. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.
Sigurdsson HP; Hefner G; Ben-Omar N; Köstlbacher A; Wenzel-Seifert K; Hiemke C; Haen E
J Neural Transm (Vienna); 2015 May; 122(5):721-9. PubMed ID: 25257248
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
3. Serum and Saliva Concentrations of Venlafaxine, O-Desmethylvenlafaxine, Quetiapine, and Citalopram in Psychiatric Patients.
Ebert K; Maurice E; Lukačin R; Fleischhaker C; Schulz E; Ebert D; Clement HW
Ther Drug Monit; 2018 Jun; 40(3):351-355. PubMed ID: 29746434
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships.
Hansen MR; Kuhlmann IB; Pottegård A; Damkier P
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):298-302. PubMed ID: 28397349
[TBL] [Abstract][Full Text] [Related]
5. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population.
Wang ZZ; Deng SH; Lu HY; Li L; Zhu XQ; Hu JQ; Xie HS; Chen HZ; Chen YQ; Zhang M; Fang ZY; Wen YG; Shang DW
Hum Psychopharmacol; 2020 May; 35(3):e2733. PubMed ID: 32239743
[TBL] [Abstract][Full Text] [Related]
6. Reduced clearance of venlafaxine in a combined treatment with quetiapine.
Paulzen M; Schoretsanitis G; Hiemke C; Gründer G; Haen E; Augustin M
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():116-121. PubMed ID: 29702137
[TBL] [Abstract][Full Text] [Related]
7. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic correlates of venlafaxine: associated adverse reactions.
Schoretsanitis G; Haen E; Hiemke C; Endres K; Ridders F; Veselinovic T; Gründer G; Paulzen M
Eur Arch Psychiatry Clin Neurosci; 2019 Oct; 269(7):851-857. PubMed ID: 30923938
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
10. Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring.
Stamm TJ; Becker D; Sondergeld LM; Wiethoff K; Hiemke C; O'Malley G; Ricken R; Bauer M; Adli M
Pharmacopsychiatry; 2014 Jul; 47(4-5):174-9. PubMed ID: 25054625
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
12. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
13. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
[TBL] [Abstract][Full Text] [Related]
14. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
[TBL] [Abstract][Full Text] [Related]
15. Sex and body weight are major determinants of venlafaxine pharmacokinetics.
Schoretsanitis G; Haen E; Hiemke C; Fay B; Unholzer S; Correll CU; Gründer G; Paulzen M
Int Clin Psychopharmacol; 2018 Nov; 33(6):322-329. PubMed ID: 30028351
[TBL] [Abstract][Full Text] [Related]
16. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.
Klamerus KJ; Parker VD; Rudolph RL; Derivan AT; Chiang ST
Pharmacotherapy; 1996; 16(5):915-23. PubMed ID: 8888087
[TBL] [Abstract][Full Text] [Related]
17. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions.
Unterecker S; Hiemke C; Greiner C; Haen E; Jabs B; Deckert J; Pfuhlmann B
Pharmacopsychiatry; 2012 Sep; 45(6):229-35. PubMed ID: 22426847
[TBL] [Abstract][Full Text] [Related]
18. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.
Haslemo T; Eliasson E; Jukić MM; Ingelman-Sundberg M; Molden E
Br J Clin Pharmacol; 2019 Jan; 85(1):194-201. PubMed ID: 30312494
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression.
Hole K; Arnestad M; Molden E; Haslemo T
J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):281-285. PubMed ID: 33905640
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
